Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAI open-label safety extension in refractory MAC lung infection
2015-003170-33Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Nov 2015
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of amikacin in Mycobacterium avium lung disease and Mycobacterium avium complex infection (MAC), sponsored by Insmed Incorporated. Primary endpoint: Safety. Started Nov 2015; status: completed.
02
Drugs
amikacin
03
Conditions
Mycobacterium avium lung diseaseMycobacterium avium complex infection (MAC)
Beyond the preview
Go deeper on 2015-003170-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003170-33.